Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL653249 | 1.00 | MBTD1 (0.39) | MBTD1L3MBTL3PARP1CHRNB2CHRNB4 | |
| SCHEMBL3061000 | 1.00 | MBTD1 (0.39) | MBTD1L3MBTL3PARP1CHRNB2CHRNB4 | |
| SCHEMBL18203996 | 0.89 | MBTD1 (0.44) | MBTD1L3MBTL3PARP1CHRNB2CHRNB4 | |
| SCHEMBL28501691 | 0.89 | L3MBTL3 (0.47) | MBTD1L3MBTL3PARP1L3MBTL1SLC1A2 | |
| SCHEMBL18203997 | 0.89 | MBTD1 (0.44) | MBTD1L3MBTL3PARP1CHRNB2CHRNB4 | |
| SCHEMBL13451547 | 0.89 | MBTD1 (0.44) | MBTD1L3MBTL3PARP1CHRNB2CHRNB4 | |
| SCHEMBL16765059 | 0.89 | L3MBTL3 (0.47) | MBTD1L3MBTL3PARP1L3MBTL1SLC1A2 | |
| SCHEMBL25391152 | 0.85 | L3MBTL3 (0.47) | MBTD1L3MBTL3PARP1CHRNB2CHRNB4 | |
| Hydrochloric Acid SCHEMBL25391154 | 0.83 | L3MBTL3 (0.46) | MBTD1L3MBTL3PARP1CHRNB2CHRNB4 | |
| SCHEMBL14224579 | 0.82 | CHRNB2 (0.52) | MBTD1L3MBTL3PARP1CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021099285-A1 | TRIAZATRICYCLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-27 | — | — | WO | disclosed |
| EP-2185555-B1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-8865702-B2 | B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-8440694-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20130005703-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN-5-HT6 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-01-03 | — | — | US | disclosed |
| US-8293913-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | SCHRIMPF MICHAEL R (US) | 2012-08-16 | — | — | US | disclosed |
| US-8119635-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2298775-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100292271-A1 | Quinoline Compounds Suitable for Treating Disorders that Respond to Modulation of the Serotonin-5-HT6 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-11-18 | — | — | US | disclosed |
| EP-2185555-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-05-19 | — | — | EP | disclosed |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| US-7598236-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2009-10-06 | — | — | US | disclosed |
| WO-2009019286-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-02-12 | — | — | WO | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2008-04-24 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | MBTD1 2997/4885L3MBTL3 4813/4885PARP1 4244/4885 |
| US-20100292271-A1 | Quinoline Compounds Suitable for Treating Disorders that Respond to Modulation of the Serotonin-5-HT6 Receptor | HTR6, HTR1A, HTR3B | MBTD1 1702/4885L3MBTL3 3711/4885PARP1 1089/4885 |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | MBTD1 2997/4885L3MBTL3 4813/4885PARP1 4244/4885 |
| US-20130005703-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN-5-HT6 RECEPTOR | HTR6, HTR1A, HTR3B | MBTD1 1837/4885L3MBTL3 3865/4885PARP1 931/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | MBTD1 2894/4885L3MBTL3 4828/4885PARP1 4042/4885 |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | MBTD1 2855/4885L3MBTL3 4298/4885PARP1 1111/4885 |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | MBTD1 2997/4885L3MBTL3 4813/4885PARP1 4244/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | MBTD1 2894/4885L3MBTL3 4828/4885PARP1 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.